How we manage immune thrombocytopenia in the elderly

British Journal of Haematology

Volumn 173, Issue 6, 2016, Pages 844-856

  Mahévas, Matthieu ^a   Michel, Marc ^a   Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

elderly; immune thrombocytopenia; rituximab; splenectomy; thrombopoietin agonists

Indexed keywords

ABCIXIMAB; AMIODARONE; AMPICILLIN; AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; EPTIFIBATIDE; ETHAMBUTOL; HALOPERIDOL; IBUPROFEN; IMMUNOGLOBULIN; IRINOTECAN; MYCOPHENOLATE MOFETIL; NAPROXEN; OXALIPLATIN; PARACETAMOL; PHENYTOIN; PIPERACILLIN; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ASEPTIC MENINGITIS; BLEEDING; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW EXAMINATION; COGNITION ASSESSMENT; COMORBIDITY; CYTOGENETICS; DRUG SAFETY; DRUG TREATMENT FAILURE; FEVER; GERIATRIC PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER TOXICITY; MEDICAL HISTORY; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY HEALTH CARE; SKIN ALLERGY; SKIN MANIFESTATION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS; TREATMENT PLANNING; TREATMENT RESPONSE; VEIN THROMBOSIS;

EID: 84973652213     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14067     Document Type: Review

References (95)

1. Ahn, Y.S., Fernandez, L.F., Kim, C.I., Mylvaganam, R., Temple, J.D. Jr, Cayer, M.L. & Harrington, W.J. (1989) Danazol therapy renders red cells resistant to osmotic lysis. FASEB Journal, 3, 157–162.
2. Ahsan, N. (1998) Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. Journal of Nephrology, 11, 157–161.
3. Andres, E., Zimmer, J., Noel, E., Kaltenbach, G., Koumarianou, A. & Maloisel, F. (2003) Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. Drugs and Aging, 20, 841–846.
4. Arnold, D.M., Dentali, F., Crowther, M.A., Meyer, R.M., Cook, R.J., Sigouin, C., Fraser, G.A., Lim, W. & Kelton, J.G. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 146, 25–33.
5. Arnold, D.M., Nazi, I., Warkentin, T.E., Smith, J.W., Toltl, L.J., George, J.N. & Kelton, J.G. (2013) Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfusion Medicine Reviews, 27, 137–145.
6. Auger, S., Duny, Y., Rossi, J.F. & Quittet, P. (2012) Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. British Journal of Haematology, 158, 386–398.
7. Bellucci, S., Charpak, Y., Chastang, C. & Tobelem, G. (1988) Low doses v conventional doses of corticosteroids in immun thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood, 71, 1165–1169.
8. Bisharat, N., Omari, H., Lavi, I. & Raz, R. (2001) Risk of infection and death among post-splenectomy patients. Journal of Infection, 43, 182–186.
9. Bizzoni, L., Mazzucconi, M.G., Gentile, M., Santoro, C., Bernasconi, S., Chiarotti, F., Foa, R. & Mandelli, F. (2006) Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. European Journal of Haematology, 76, 210–216.
10. Bourgeois, E., Caulier, M.T., Delarozee, C., Brouillard, M., Bauters, F. & Fenaux, P. (2003) Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. British Journal of Haematology, 120, 1079–1088.
11. British Committee for Standards in Haematology General Haematology Task Force. (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. British Journal of Haematology, 120, 574–596.
12. Brynes, R.K., Orazi, A., Theodore, D., Burgess, P., Bailey, C.K., Thein, M.M. & Bakshi, K.K. (2015) Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. American Journal of Hematology, 90, 598–601.
13. Bufalari, A., Ferri, M., Cao, P., Cirocchi, R., Bisacci, R. & Moggi, L. (1996) Surgical care in octogenarians. British Journal of Surgery, 83, 1783–1787.
14. Bussel, J.B. & Lakkaraja, M. (2014) Thrombopoietic agents: there is still much to learn. Presse Medicale (Paris, France: 1983), 43, e69–e78.
15. Bussel, J.B., Lee, C.S., Seery, C., Imahiyerobo, A.A., Thompson, M.V., Catellier, D., Turenne, I.G., Patel, V.L., Basciano, P.A., Elstrom, R.L. & Ghanima, W. (2014) Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica, 99, 1264–1271.
16. Carbone, J. (2007) Adverse reactions and pathogen safety of intravenous immunoglobulin. Current Drug Safety, 2, 9–18.
17. Cheng, Y., Wong, R.S., Soo, Y.O., Chui, C.H., Lau, F.Y., Chan, N.P., Wong, W.S. & Cheng, G. (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. New England Journal of Medicine, 349, 831–836.
18. Cheng, G., Saleh, M.N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., Arning, M., Stone, N.L. & Bussel, J.B. (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, 377, 393–402.
19. Choi, P.Y., Roncolato, F., Badoux, X., Ramanathan, S., Ho, S.J. & Chong, B.H. (2015) A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood, 126, 500–503.
20. Cines, D.B. & Blanchette, V.S. (2002) Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995–1008.
21. Cines, D.B. & Bussel, J.B. (2005) How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 106, 2244–2251.
22. Cohen, Y.C., Djulbegovic, B., Shamai-Lubovitz, O. & Mozes, B. (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Archives of Internal Medicine, 160, 1630–1638.
23. Cooper, N., Stasi, R., Cunningham-Rundles, S., Feuerstein, M.A., Leonard, J.P., Anadori, S. & Bussel, J.B. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 125, 232–239.
24. Cortelazzo, S., Finazzi, G., Buelli, M., Molteni, A., Viero, P. & Barbui, T. (1991) High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood, 77, 31–33.
25. Cuker, A. & Cines, D.B. (2010) Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia? Hematology American Society of Hematology Education Program, 2010, 385–386.
26. Daou, S., Federici, L., Zimmer, J., Maloisel, F., Serraj, K. & Andres, E. (2008) Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. European Journal of Internal Medicine, 19, 447–451.
27. Dierickx, D., Verhoef, G., Van Hoof, A., Mineur, P., Roest, A., Triffet, A., Kentos, A., Pierre, P., Boulet, D., Bries, G., Lê, P.Q., Janssens, A. & Delannoy, A. (2009) Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. Journal of Internal Medicine, 266, 484–491.
28. Donato, A.J., Morgan, R.G., Walker, A.E. & Lesniewski, L.A. (2015) Cellular and molecular biology of aging endothelial cells. Journal of Molecular and Cellular Cardiology, 89, 122–135.
29. Frederiksen, H. & Schmidt, K. (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood, 94, 909–913.
30. Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. & Radford, M.J. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 285, 2864–2870.
31. Gaines, A.R. (2000) Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood, 95, 2523–2529.
32. Garbe, E., Andersohn, F., Bronder, E., Salama, A., Klimpel, A., Thomae, M., Schrezenmeier, H., Hildebrandt, M., Spath-Schwalbe, E., Gruneisen, A., Meyer, O. & Kurtal, H. (2012) Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. European Journal of Clinical Pharmacology, 68, 821–832.
33. Garcia-Manero, G. (2015) Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. American Journal of Hematology, 90, 831–841.
34. George, J.N. & Aster, R.H. (2009) Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology American Society of Hematology Education Program, 2009, 153–158.
35. Ghanima, W., Geyer, J.T., Lee, C.S., Boiocchi, L., Imahiyerobo, A.A., Orazi, A. & Bussel, J.B. (2014) Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica, 99, 937–944.
36. Giagounidis, A., Mufti, G.J., Fenaux, P., Sekeres, M.A., Szer, J., Platzbecker, U., Kuendgen, A., Gaidano, G., Wiktor-Jedrzejczak, W., Hu, K., Woodard, P., Yang, A.S. & Kantarjian, H.M. (2014) Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer, 120, 1838–1846.
37. Godeau, B. & Bierling, P. (2003) High-dose dexamethasone as initial treatment for immune thrombocytopenic purpura. New England Journal of Medicine, 349, 2267–2268 (letter).
38. Godeau, B., Durand, J.M., Roudot-Thoraval, F., Tenneze, A., Oksenhendler, E., Kaplanski, G., Schaeffer, A. & Bierling, P. (1997) Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. British Journal of Haematology, 97, 336–339.
39. Godeau, B., Chevret, S., Varet, B., Lefrere, F., Zini, J.M., Bassompierre, F., Cheze, S., Legouffe, E., Hulin, C., Grange, M.J., Fain, O. & Bierling, P. & French ATIP Study Group. (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet, 359, 23–29.
40. Godeau, B., Porcher, R., Fain, O., Lefrere, F., Fenaux, P., Cheze, S., Vekhoff, A., Chauveheid, M.P., Stirnemann, J., Galicier, L., Bourgeois, E., Haiat, S., Varet, B., Leporrier, M., Papo, T., Khellaf, M., Michel, M. & Bierling, P. (2008) Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, 112, 999–1004.
41. Gonzalez-Porras, J.R., Escalante, F., Pardal, E., Sierra, M., Garcia-Frade, L.J., Redondo, S., Arefi, M., Aguilar, C., Ortega, F., deCabo, E., Fisac, R.M., Sanz, O., Esteban, C., Alberca, I., Sanchez-Barba, M., Santos, M.T., Fernandez, A. & Gonzalez-Lopez, T.J. & Grupo de Trombosis y Hemostasia de Castilla y León. (2013) Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. European Journal of Haematology, 91, 236–241.
42. Gudbrandsdottir, S., Birgens, H.S., Frederiksen, H., Jensen, B.A., Jensen, M.K., Kjeldsen, L., Klausen, T.W., Larsen, H., Mourits-Andersen, H.T., Nielsen, C.H., Nielsen, O.J., Plesner, T., Pulczynski, S., Rasmussen, I.H., Ronnov-Jessen, D. & Hasselbalch, H.C. (2013) Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood, 121, 1976–1981.
43. Hadjadj, J., Michel, M., Chauveheid, M.P., Godeau, B., Papo, T. & Sacre, K. (2014) Immune thrombocytopenia in chronic myelomonocytic leukemia. European Journal of Haematology, 93, 521–526.
44. Hasan, A., Michel, M., Patel, V., Stasi, R., Cunningham-Rundles, S., Leonard, J.P. & Bussel, J. (2009) Repeated courses of rituximab in chronic ITP: three different regimens. American Journal of Hematology, 84, 661–665.
45. Hernandez, F., Linares, M., Colomina, P., Pastor, E., Cervero, A., Perez, A. & Perella, M. (1995) Dapsone for refractory chronic idiopathic thrombocytopenic purpura. British Journal of Haematology, 90, 473–475.
46. Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L. & Berger, D.P. (2010) Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 116, 3163–3170.
47. Kavic, S.M., Segan, R.D. & Park, A.E. (2005) Laparoscopic splenectomy in the elderly: a morbid procedure? Surgical Endoscopy, 19, 1561–1564.
48. Khan, M., Kristy, B., Kadia, T., Ferrajoli, A., Alvarado, Y., Borthakur, G., Pemmaraju, N., Konopleva, M., Garcia-Manero, G. & DiNardo, C. (2015) Efficacy and safety of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure: a phase 2 clinical trial. Blood, 126, 1691.
49. Khellaf, M., Michel, M., Schaeffer, A., Bierling, P. & Godeau, B. (2005) Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica, 90, 829–832.
50. Khellaf, M., Charles-Nelson, A., Fain, O., Terriou, L., Viallard, J.F., Cheze, S., Graveleau, J., Slama, B., Audia, S., Ebbo, M., Le Guenno, G., Cliquennois, M., Salles, G., Bonmati, C., Teillet, F., Galicier, L., Hot, A., Lambotte, O., Lefrere, F., Sacko, S., Kengue, D.K., Bierling, P., Roudot-Thoraval, F., Michel, M. & Godeau, B. (2014) Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood, 124, 3228–3236.
51. Kojouri, K., Vesely, S.K., Terrell, D.R. & George, J.N. (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 104, 2623–2634.
52. Kwok, B., Hall, J.M., Witte, J.S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al Hafidh, J., Balmert, E., Vaupel, C., El Hader, C., McGinniss, M.J., Nahas, S.A., Kines, J. & Bejar, R. (2015) MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood, 126, 2355–2361.
53. Lopez-Jimenez, L., Montero, M., Gonzalez-Fajardo, J.A., Arcelus, J.I., Suarez, C., Lobo, J.L., Monreal, M. & RIETE investigators. (2006) Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica, 91, 1046–1051.
54. Maloisel, F., Andres, E., Zimmer, J., Noel, E., Zamfir, A., Koumarianou, A. & Dufour, P. (2004) Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. American Journal of Medicine, 116, 590–594.
55. Matzdorff, A. & Beer, J.H. (2013) Immune thrombocytopenia patients requiring anticoagulation–maneuvering between Scylla and Charybdis. Seminars in Hematology, 50, S83–S88.
56. Mazzucconi, M.G., Fazi, P., Bernasconi, S., De Rossi, G., Leone, G., Gugliotta, L., Vianelli, N., Avvisati, G., Rodeghiero, F., Amendola, A., Baronci, C., Carbone, C., Quattrin, S., Fioritoni, G., D'Alfonso, G., Mandelli, F. & for the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. (2007) Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood, 109, 1401–1407.
57. Michel, M., Rauzy, O.B., Thoraval, F.R., Languille, L., Khellaf, M., Bierling, P. & Godeau, B. (2011) Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. American Journal of Hematology, 86, 980–984.
58. Michel, M., Suzan, F., Adoue, D., Bordessoule, D., Marolleau, J.P., Viallard, J.F. & Godeau, B. (2015a) Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. British Journal of Haematology, 170, 218–222.
59. Michel, M., Wasser, J., Godeau, B., Aledort, L., Cooper, N., Tomiyama, Y., Khellaf, M. & Wang, X. (2015b) Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged >/=65 years with immune thrombocytopenia. Annals of Hematology, 94, 1973–1980.
60. Morbieu, C., Brunetti, F., Baranès, L., Languille, L., Limal, N., Loustau, V., Bierling, P., Michel, B., Godeau, B. & Mahévas, M. (2015) Portal or splenic vein thrombosis after splenectomy for immune cytopenia: a retrospective cohort study. ASH57th Annual Meeting and exposition. December 5–7, Orlando.
61. Moulis, G., Palmaro, A., Montastruc, J.L., Godeau, B., Lapeyre-Mestre, M. & Sailler, L. (2014) Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood, 124, 3308–3315.
62. Moulis, G., Palmaro, A., Sailler, L. & Lapeyre-Mestre, M. (2015) Corticosteroid risk function of severe infection in primary immune thrombocytopenia adults. a nationwide nested case-control study. PLoS ONE, 10, e0142217.
63. Mughal, T.I., Cross, N.C., Padron, E., Tiu, R.V., Savona, M., Malcovati, L., Tibes, R., Komrokji, R.S., Kiladjian, J.J., Garcia-Manero, G., Orazi, A., Mesa, R., Maciejewski, J.P., Fenaux, P., Itzykson, R., Mufti, G., Solary, E. & List, A.F. (2015) An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica, 100, 1117–1130.
64. Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L. Jr & Crowther, M.A. (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 117, 4190–4207.
65. Neylon, A.J., Saunders, P.W., Howard, M.R., Proctor, S.J. & Taylor, P.R. & Northern Region Haematology Group. (2003) Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. British Journal of Haematology, 122, 966–974.
66. Oger, E., Bressollette, L., Nonent, M., Lacut, K., Guias, B., Couturaud, F., Leroyer, C. & Mottier, D. (2002) High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thrombosis and Haemostasis, 88, 592–597.
67. Olney, H.J., Pabinger, I., Mayer, B., Bakshi, K., Bailey, C.K. & Brainsky, A. (2011) Efficacy and safety of eltrombopag in elderly patients with chronic immune thrombocytopenia: analysis of five clinical trials. Blood (ASH Annual Meeting Abstracts), 118, Abstract 3294.
68. Patel, V.L., Mahevas, M., Lee, S.Y., Stasi, R., Cunningham-Rundles, S., Godeau, B., Kanter, J., Neufeld, E., Taube, T., Ramenghi, U., Shenoy, S., Ward, M.J., Mihatov, N., Patel, V.L., Bierling, P., Lesser, M., Cooper, N. & Bussel, J.B. (2012) Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, 119, 5989–5995.
69. Pengo, V., Legnani, C., Noventa, F., Palareti, G. & Group, I.S. (2001) Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thrombosis and Haemostasis, 85, 418–422.
70. Portielje, J.E., Westendorp, R.G., Kluin-Nelemans, H.C. & Brand, A. (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood, 97, 2549–2554.
71. Provan, D., Stasi, R., Newland, A.C., Blanchette, V.S., Bolton-Maggs, P., Bussel, J.B., Chong, B.H., Cines, D.B., Gernsheimer, T.B., Godeau, B., Grainger, J., Greer, I., Hunt, B.J., Imbach, P.A., Lyons, G., McMillan, R., Rodeghiero, F., Sanz, M.A., Tarantino, M., Watson, S., Young, J. & Kuter, D.J. (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 115, 168–186.
72. Radaelli, F., Calori, R., Goldaniga, M., Guggiari, E. & Luciano, A. (1999) Adult refractory chronic idiopathic thrombocytopenic purpura: can dapsone be proposed as second-line therapy? British Journal of Haematology, 104, 641–642.
73. Reese, J.A., Li, X., Hauben, M., Aster, R.H., Bougie, D.W., Curtis, B.R., George, J.N. & Vesely, S.K. (2010) Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood, 116, 2127–2133.
74. Rivière, É., Viallard, J., Guy, A., Kilani, B., Vieira-Dias, J., Pons, A., Couffinhal, T., Pellegrin, J.L. & James, C. (2015) Intrinsically impaired platelet production in some patients with persistent or chronic immune thrombocytopenia. British Journal of Haematology, 170, 408–415.
75. Rizvi, H., Butler, T., Calaminici, M., Doobaree, I.U., Nandigam, R.C., Bennett, D., Provan, D. & Newland, A.C. (2015) United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. British Journal of Haematology, 169, 590–594.
76. Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., Bussel, J.B., Cines, D.B., Chong, B.H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M.G., McMillan, R., Sanz, M.A., Imbach, P., Blanchette, V., Kuhne, T., Ruggeri, M. & George, J.N. (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 113, 2386–2393.
77. Rodrigo, C. & Gooneratne, L. (2013) Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. Journal of Thrombosis and Haemostasis, 11, 1946–1953.
78. Ruggeri, M., Tosetto, A., Palandri, F., Polverelli, N., Mazzucconi, M.G., Santoro, C., Gaidano, G., Lunghi, M., Zaja, F., De Stefano, V., Sartori, R., Fazi, P. & Rodeghiero, F., for the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311. (2014) Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. Journal of Thrombosis and Haemostasis, 12, 1266–1273.
79. Salama, A., Kiesewetter, H., Kalus, U., Movassaghi, K. & Meyer, O. (2008) Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thrombosis and Haemostasis, 100, 762–765.
80. Sauvetre, G., MahEvas, M., Limal, N., Guillaud, C., Khellaf, M., Bierling, P., Languille, L., Delbos, F., Noizat-Pirenne, F., Michel, M. & Godeau, B. (2015) Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. American Journal of Hematology, 90, E201–E202.
81. Scaradavou, A., Woo, B., Woloski, B.M., Cunningham-Rundles, S., Ettinger, L.J., Aledort, L.M. & Bussel, J.B. (1997) Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood, 89, 2689–2700.
82. Schoonen, W.M., Kucera, G., Coalson, J., Li, L., Rutstein, M., Mowat, F., Fryzek, J. & Kaye, J.A. (2009) Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. British Journal of Haematology, 145, 235–244.
83. Stiehm, E.R. (2013) Adverse effects of human immunoglobulin therapy. Transfusion Medicine Reviews, 27, 171–178.
84. Stirnemann, J., Kaddouri, N., Khellaf, M., Morin, A.S., Prendki, V., Michel, M., Mekinian, A., Bierling, P., Fenaux, P., Godeau, B. & Fain, O. (2016) Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. European Journal of Haematology, 96, 269–275.
85. Tamez-Perez, H.E., Quintanilla-Flores, D.L., Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J.G. & Tamez-Pena, A.L. (2015) Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: a narrative review. World Journal of Diabetes, 6, 1073–1081.
86. Thaler, J., Pabinger, I. & Ay, C. (2015) Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art. Frontiers in Cardiovascular Medicine. Jul 14; 2, 30.
87. Thomsen, R.W., Schoonen, W.M., Farkas, D.K., Riis, A., Jacobsen, J., Fryzek, J.P. & Sorensen, H.T. (2009) Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Annals of Internal Medicine, 151, 546–555.
88. Valent, P., Bain, B.J., Bennett, J.M., Wimazal, F., Sperr, W.R., Mufti, G. & Horny, H.P. (2012) Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leukemia Research, 36, 1–5.
89. Vancine-Califani, S.M., De Paula, E.V., Ozelo, M.C., Orsi, F.L., Fabri, D.R. & Annichino-Bizzacchi, J.M. (2008) Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets, 19, 489–495.
90. Vianelli, N., Valdre, L., Fiacchini, M., de Vivo, A., Gugliotta, L., Catani, L., Lemoli, R.M., Poli, M. & Tura, S. (2001) Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica, 86, 504–509.
91. Vianelli, N., Palandri, F., Polverelli, N., Stasi, R., Joelsson, J., Johansson, E., Ruggeri, M., Zaja, F., Cantoni, S., Catucci, A.E., Candoni, A., Morra, E., Bjorkholm, M., Baccarani, M. & Rodeghiero, F. (2013) Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica, 98, 875–880.
92. Wei, Y., Ji, X.B., Wang, Y.W., Wang, J.X., Yang, E.Q., Wang, Z.C., Sang, Y.Q., Bi, Z.M., Ren, C.A., Zhou, F., Liu, G.Q., Peng, J. & Hou, M. (2016) High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood, 127, 296–302.
93. Zaja, F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Zaccaria, A., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., Campagna, S., Ferrara, F., Angelucci, E., Usala, E., Cantoni, S., Visani, G., Fornaro, A., Rizzi, R., De Stefano, V., Casulli, F., Battista, M.L., Isola, M., Soldano, F., Gamba, E. & Fanin, R. (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood, 115, 2755–2762.
94. Zaja, F., Marin, L., Chiozzotto, M., Puglisi, S., Volpetti, S. & Fanin, R. (2012) Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. American Journal of Hematology, 87, 321–323.
95. Zhou, H., Fu, R., Wang, H., Zhou, F., Li, H., Zhou, Z., Zhang, L. & Yang, R. (2013) Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. Annals of Hematology, 92, 79–87.